Sangamo Therapeutics (SGMO)
OTHER OTC:SGMO
Want to see SGMO full AI Analyst Report?
Top Page
Sangamo Therapeutics
(OTC:SGMO)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.14
▼(-46.15% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by weak financial performance (declining revenue, large losses, heavy cash burn, and negative equity implying high financing/dilution risk) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by constructive earnings-call developments on ST-920’s regulatory path and durability data, though timing and execution remain funding-dependent amid listing-related headwinds.
Positive Factors
Regulatory clarity for ST-920
Agreement with FDA on an accelerated approval endpoint and acceptance of 104-week confirmatory data materially reduces regulatory uncertainty for ST-920. This durable clarity shortens development risk, increases the likelihood of milestone-triggered partner payments, and strengthens long-term commercialization odds.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flow at ~-$90M TTM is a structural constraint: it forces frequent capital raises, dilutes shareholders, and diverts management to financing rather than R&D. Over months this limits the company’s ability to complete filings and commercial preparation without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity for ST-920
Agreement with FDA on an accelerated approval endpoint and acceptance of 104-week confirmatory data materially reduces regulatory uncertainty for ST-920. This durable clarity shortens development risk, increases the likelihood of milestone-triggered partner payments, and strengthens long-term commercialization odds.
Read all positive factors
Sangamo Therapeutics (SGMO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$62.56M
Dividend YieldN/A
Average Volume (3M)7.65M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-45.80%
EPS Growth-0.16%
CountryUS
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue2.40
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$2.00Price Target Upside669.23% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$35.67M
Sangamo Therapeutics Business Overview & Revenue Model
Company Description
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, gen...
How the Company Makes Money
Sangamo has historically generated most of its revenue from collaboration-related income rather than product sales. Key revenue streams have included (1) upfront payments received when entering new collaboration or license agreements; (2) research...
Sangamo Therapeutics Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.Positive Updates
BLA Rolling Submission Progress for ST-920 (Fabry)
First 2 modules of the rolling BLA for ST-920 submitted; company states the rolling submission is ~3/5 complete and anticipates completing the BLA submission as early as this summer, subject to adequate funding. FDA affirmed accelerated approval pathway using mean annualized eGFR slope at 52 weeks across all 32 dosed patients.
Negative Updates
NASDAQ Delisting Determination and Market Transition
Received a delisting determination from NASDAQ due to noncompliance with minimum bid requirements; common stock transitioned to trading on the OTCQB Venture Market under the same ticker (SGMO); company intends to appeal at a June hearing.
Read all updates
Q1-2026 Updates
Positive
Negative
BLA Rolling Submission Progress for ST-920 (Fabry)
First 2 modules of the rolling BLA for ST-920 submitted; company states the rolling submission is ~3/5 complete and anticipates completing the BLA submission as early as this summer, subject to adequate funding. FDA affirmed accelerated approval pathway using mean annualized eGFR slope at 52 weeks across all 32 dosed patients.
Read all positive updates
Company Guidance
Sangamo said the rolling BLA for ST‑920 is in progress with the first two modules submitted, the clinical module (1‑year data) already filed, management characterizing the filing as roughly 3/5 complete and anticipating BLA completion “as early as this summer” subject to securing additional funding; the FDA agreed accelerated approval can be based on mean annualized eGFR slope at 52 weeks across all 32 dosed patients, affirmed no additional confirmatory trial is required, and indicated 104‑week (2‑year) data across those 32 patients may be used for full approval (the last patient reached the 2‑year time point around April). Management also highlighted durability and safety — four patients beyond five years with supraphysiological alpha‑Gal and 17 patients off ERT (some >3 years) — and operational progress in neurology with six sites activated for the Phase I/II STAND (ST‑503), GLP toxicology for ST‑506 completed with analysis ongoing, and MHRA alignment on key matters.Sangamo Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.56M | 39.55M | 57.80M | 176.23M | 111.30M | 110.70M |
| Gross Profit | 34.56M | 31.95M | 57.80M | 176.23M | 99.19M | 110.70M |
| EBITDA | -117.46M | -115.90M | -89.09M | -96.80M | -179.74M | -160.35M |
| Net Income | -123.33M | -122.93M | -97.94M | -257.83M | -192.28M | -178.29M |
Balance Sheet | ||||||
| Total Assets | 59.97M | 59.74M | 101.64M | 165.32M | 562.51M | 721.92M |
| Cash, Cash Equivalents and Short-Term Investments | 27.59M | 20.95M | 41.92M | 81.00M | 277.63M | 376.55M |
| Total Debt | 19.33M | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Total Liabilities | 78.92M | 74.01M | 78.86M | 82.43M | 267.55M | 346.58M |
| Stockholders Equity | -18.95M | -14.27M | 22.77M | 82.89M | 294.96M | 375.34M |
Cash Flow | ||||||
| Free Cash Flow | -90.46M | -97.31M | -67.41M | -246.00M | -243.80M | -256.53M |
| Operating Cash Flow | -90.34M | -97.21M | -67.14M | -224.84M | -223.63M | -233.25M |
| Investing Cash Flow | -115.00K | -102.00K | 37.52M | 153.53M | 59.28M | 248.20M |
| Financing Cash Flow | 89.31M | 70.75M | 28.38M | 14.59M | 84.66M | 32.86M |
Sangamo Therapeutics Technical Analysis
Negative
0.26
Price Trends
0.19
Negative
0.29
Negative
0.40
Negative
Market Momentum
>-0.01
Positive
44.68
Neutral
18.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.19, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.68 is Neutral, neither overbought nor oversold. The STOCH value of 18.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.
Sangamo Therapeutics Risk Analysis
Sangamo Therapeutics disclosed 62 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sangamo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $283.43M | -1.85 | -2748.16% | ― | ― | 43.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $100.28M | -2.28 | -36.37% | ― | -100.00% | -1056.82% | |
46 Neutral | $158.19M | -1.19 | -100.13% | ― | 12.96% | 12.51% | |
43 Neutral | $62.56M | -0.52 | 6686.36% | ― | -45.80% | -0.16% | |
43 Neutral | $490.79M | -1.92 | -131.58% | ― | ― | 22.16% |
* Healthcare Sector Average
SGMO
Sangamo Therapeutics
0.17
-0.33
-67.00%
CABA
Cabaletta Bio
3.01
1.07
55.15%
BDTX
Black Diamond Therapeutics
1.72
-0.67
-28.03%
ELTX
Elicio Therapeutics
4.08
-3.63
-47.05%
CRBU
Caribou Biosciences
1.66
0.54
48.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.